Showing 6,049 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Bad science & bogus treatments

Gammora does not cure HIV

News
6 November 2018
Treatment simplification strategies

Dolutegravir plus darunavir maintains viral suppression without NRTIs

News
6 November 2018
Injectable & long-acting HIV treatment

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

Editor's pick
Poz
5 November 2018
Heterosexual men

Reaching the men: who are the partners of the young women with HIV in South Africa?

News
5 November 2018
People with limited treatment options

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

News
2 November 2018
PrEP science

How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects

News
2 November 2018
Undetectable viral load & treatment as prevention

aidsmapLIVE: AIDS 2018 special Video

November 2018
Cardiovascular disease

Cardiovascular Risk Unclear for HIV Patients on Dolutegravir

Editor's pick
Medscape (requires free registration)
1 November 2018
Starting treatment

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

Editor's pick
Janssen press release
1 November 2018
Starting treatment

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Editor's pick
Gilead press release
1 November 2018
Starting treatment

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

News
1 November 2018
Bad science & bogus treatments

'No cure' for HIV in Zimbabwe says UN, following claims from local preacher

Editor's pick
UN News
1 November 2018
Injectable & long-acting PrEP

Beyond Truvada – what is the future of PrEP?

News
31 October 2018
Starting treatment

Bictegravir matches dolutegravir in first-line treatment

News
31 October 2018
New & experimental HIV treatments

Long-lasting HIV injection is a step closer after second GSK study

Editor's pick
Reuters
31 October 2018
Treatment simplification strategies

Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

News
30 October 2018
New & experimental HIV treatments

First large HIV prevention trial using antibodies will probably not be the last

News
29 October 2018
The search for a cure

The Miami monkey cured with two antibodies

News
26 October 2018
Injectable & long-acting PrEP

The long tail of injectable PrEP is especially long for women

News
25 October 2018
Adherence

How substance use affects adherence to PrEP among gay and bisexual men

Editor's pick
Medical Xpress
24 October 2018
Child developmental issues

Dolutegravir Use During Pregnancy: What Are the Risks?

Editor's pick
Infectious Disease Advisor
22 October 2018
Health monitoring in resource-limited settings

Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds

News
22 October 2018
New & experimental HIV treatments

ViiV Seeks FDA Approval for Two-Drug HIV Treatment

Editor's pick
Poz
22 October 2018
The search for a cure

Gilead and Aelix join forces to pursue HIV 'cure'

Editor's pick
PMLiVE
18 October 2018